Clovis Oncology (CLVS) Misses Q1 EPS by 18c

Clovis Oncology (NASDAQ: CLVS) reported Q1 EPS of ($1.54), $0.18 worse than the analyst estimate of ($1.36). Revenue for the quarter came in at $18.5 million versus the consensus estimate of $18.33 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Plexus Corp (PLXS) Tops Q2 EPS by 7c
• Core Laboratories (CLB) Misses Q1 EPS by 13c